MHTX (Manhattan Scientifics) Total Liabilities: $3.47 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Manhattan Scientifics Total Liabilities?

Manhattan Scientifics MHTX -95.00% Total Liabilities is $3.47 Mil as of Jun. 2024.

Manhattan Scientifics's Total Liabilities for the quarter that ended in Jun. 2024 was $3.47 Mil.

Manhattan Scientifics's quarterly Total Liabilities increased from Dec. 2023 ($3.18 Mil) to Mar. 2024 ($3.33 Mil) and increased from Mar. 2024 ($3.33 Mil) to Jun. 2024 ($3.47 Mil).

Manhattan Scientifics's annual Total Liabilities increased from Dec. 2021 ($2.42 Mil) to Dec. 2022 ($2.73 Mil) and increased from Dec. 2022 ($2.73 Mil) to Dec. 2023 ($3.18 Mil).


Manhattan Scientifics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Manhattan Scientifics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Manhattan Scientifics Total Liabilities Chart

Manhattan Scientifics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.23 2.17 2.42 2.73 3.18

Manhattan Scientifics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 3.04 3.18 3.33 3.47

Manhattan Scientifics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Manhattan Scientifics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=0.316--2.86
=3.18

Manhattan Scientifics's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=0.074--3.4
=3.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $3.47 Mil mean?
Manhattan Scientifics (MHTX) has a Total Liabilities of $3.47 Mil as of Jun. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Manhattan Scientifics and its competitors.
Is Manhattan Scientifics' Total Liabilities too high?
Manhattan Scientifics' current Total Liabilities is $3.47 Mil.
How does Manhattan Scientifics' Total Liabilities compare to TBIO and CUTRQ?
Manhattan Scientifics' Total Liabilities of $3.47 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Manhattan Scientifics and its competitors. Manhattan Scientifics's current Total Liabilities is $3.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Manhattan Scientifics stock overvalued right now?
Manhattan Scientifics (MHTX) has a current Total Liabilities of $3.47 Mil. The current Total Liabilities is $3.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Manhattan Scientifics (MHTX), the current Total Liabilities is $3.47 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Manhattan Scientifics Business Description

Address 244 Fifth Avenue, Suite 2341, New York, NY, USA, 10001
Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. Its current focus is on the development of nanomaterials through the acquisition of Metallicum.